Pathology, research and practice最新文献

{"title":"Clinicopathological analysis of lymphoepithelioma-like intrahepatic cholangiocarcinoma","authors":"Haifeng Li ,&nbsp;Sidong Xie ,&nbsp;Sihong Liang ,&nbsp;Yuhang Pan ,&nbsp;Weizhen Lin ,&nbsp;Na Cheng ,&nbsp;Jing Zhou ,&nbsp;Chunkui Shao ,&nbsp;Jianning Chen","doi":"10.1016/j.prp.2025.155848","DOIUrl":"10.1016/j.prp.2025.155848","url":null,"abstract":"<div><div>We aimed to identify the clinicopathological features of lymphoepithelioma-like intrahepatic cholangiocarcinoma (LEL-ICC), and EBV latency pattern and sequence variations of EBV-associated LEL-ICC. The clinical and pathological information of nine cases of LEL-ICC diagnosed in Department of Pathology, the Third Affiliated Hospital of Sun Yat-sen University from January 2015 to October 2022 were collected. EBV latency pattern and sequence variations of EBV-associated LEL-ICC were investigated. There were 3 males and 6 females with a median age of 47 years in our cases. The morphological feature was the poorly differentiated or undifferentiated tumor cells surrounded by densely tumor infiltrating lymphocytes. Immunohistochemical staining showed the tumor cells were positive for CK7 and/or CK19, negative for HepPar-1 and Arginase-1. Eight cases showed positive nuclear signal in tumor cells by <em>in situ</em> hybridization of EBER. Five surgical specimens of EBV-associated LEL-ICC were positive for EBNA1 and negative for EBNA2, LMP1 and ZEBRA by immunohistochemestry. The type A strain, type f, type I, and del-LMP1 variants were found in EBV-associated LEL-ICC patients. LEL-ICC is a rare subtype of ICC and the accurate diagnosis mainly depends on typical histopathology, immunohistochemistry and <em>in situ</em> hybridization for EBER. The latency pattern in EBV-associated LEL-ICC patients was probably latency type I, the mainly EBV genotypes were perhaps type A strain, type f, type I and del-LMP1 variants.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155848"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic impact of PBRM1 immunohistochemical expression and its association with CD3 + and CD8 + immune cells in patients with renal cell carcinoma: A retrospective study","authors":"Amira Emad Elwy ,&nbsp;Mahmoud Ismail Nassar ,&nbsp;Shimaa Hassan Shaban ,&nbsp;Tarek Mohamed Elsaba","doi":"10.1016/j.prp.2025.155863","DOIUrl":"10.1016/j.prp.2025.155863","url":null,"abstract":"<div><div>The objective of this study is to determine the prognostic implications of PBRM1 immunohistochemical (IHC) expression in renal cell carcinoma (RCC) patients. Additionally, the objective is extended to evaluate the association between PBRM1 expression and CD3 + and CD8 + immune infiltrates. This study retrospectively reviewed 115 RCC patients who underwent nephrectomy. Immunohistochemistry was performed for PBRM1, CD3, and CD8. The associations between the studied parameters and variable clinicopathological characteristics, including survival, were analyzed statistically. A significant association was observed between the low expression of PBRM1 (&lt; 50 %) and aggressive clinicopathologic features (p value around 0.001), as well as a significantly worse 3-year overall survival (OS) and disease-free survival (DFS) (p value around 0.001). PBRM1 low expression was considered an independent predictor of shortened DFS in multivariate analysis (p = 0.030). In addition, PBRM1 expression was incorporated into the SSPN scoring system (stage, sarcomatoid, PBRM1 expression, and necrosis) for recurrence risk stratification. The four risk groups exhibited substantial disparities in OS and DFS (p &lt; 0.001). Moreover, a robust correlation was observed between the high density of immune infiltrate (number of CD3 + and CD8 + immune cells/mm²) and the low expression of PBRM1 (p &lt; 0.001). In conclusion, poor prognosis and tumor progression are strongly associated with a low expression of PBRM1. Postoperative recurrence can be accurately predicted by the SSPN score, which incorporates PBRM1 expression and clinicopathologic findings. Patients with high-risk factors associated with low expression of PBRM1 and a dense inflamed microenvironment could potentially benefit from effective immunotherapy and target treatment.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155863"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the value of anoikis-related genes in prognosis, immune microenvironment, and drug sensitivity of laryngeal squamous cell carcinoma","authors":"Cheng Wang ,&nbsp;Ge Gao ,&nbsp;Qin Che ,&nbsp;Shikang Zheng ,&nbsp;Ying Yang ,&nbsp;Tian Li ,&nbsp;Xingyou Zhai ,&nbsp;Yuehao Lu ,&nbsp;Bangqing Huang ,&nbsp;Ting Yu ,&nbsp;Kai Zhao ,&nbsp;Mingbo Liu","doi":"10.1016/j.prp.2025.155849","DOIUrl":"10.1016/j.prp.2025.155849","url":null,"abstract":"<div><h3>Background</h3><div>Laryngeal squamous cell carcinoma (LSCC) is a prevalent malignancy characterized by high metastatic potential and poor prognosis. Anoikis, an apoptotic pathway triggered by detachment from the extracellular matrix (ECM), acts as a barrier against cancer metastasis, so it is necessary to explore the role of anoikis-related genes (ARGs) in LSCC.</div></div><div><h3>Methods</h3><div>Multivariate Cox regression analysis was used to construct prognostic model. A nomogram integrating risk scores with clinicopathological characteristics was constructed for prognosis. Spearman correlation analysis linked ARGs to the tumor microenvironment (TME) and immune infiltration. We also predicted IC50 values for various chemotherapeutic agents by risk group and selected three drugs (LGK974, OSI-027, and OF-1) for molecular docking with MMP3. TCGA datasets was used to evaluate the expression profile of MMP3 and TIMP1 in LSCC. In vitro assays were conducted to confirm the function of target gene in LSCC.</div></div><div><h3>Results</h3><div>We identified 19 ARGs associated with LSCC prognosis and developed a prognostic model, which subsequently classified patients into high- and low-risk groups based on median risk scores. Nomogram we established demonstrated excellent predictive performance. Low-risk individuals exhibited significantly higher immunophenotype (IPS) scores and elevated levels of immune cell components than high-risk counterparts (<em>p</em> &lt; 0.05). MMP3 demonstrating strong binding affinity with selected drugs. Analysis of TCGA datasets revealed higher TIMP1 and MMP3 expression in LSCC tissues.</div></div><div><h3>Conclusions</h3><div>Our prognostic signature effectively predicts LSCC prognosis, with MMP3 identified as a potential novel biomarker for LSCC treatment. Furthermore, our findings underscore the critical role of immune-based therapies in improving outcomes, especially for low-risk patients.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155849"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential roles of IL-17B and IL-17RB in colorectal cancer: Correlation with immune infiltration and prognosis","authors":"Han Wang ,&nbsp;Yuqi Liu ,&nbsp;Lijuan Yang ,&nbsp;Zhenjiang Wang ,&nbsp;Qinlong Hou ,&nbsp;Jihong Zhang ,&nbsp;Weili Huang ,&nbsp;Dongrui Ma ,&nbsp;Yanbo Liu","doi":"10.1016/j.prp.2025.155847","DOIUrl":"10.1016/j.prp.2025.155847","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The aim of the research is to investigate correlation of immune infiltration between IL-17B and IL-17RB in colorectal cancer (CRC), then provide an experimental basis for clinical diagnostic marker screening of CRC.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Gene expression levels were assessed via TIMER and GEPIA databases, protein expression through the Human Protein Atlas (HPA), clinicopathological correlations and prognosis via UALCAN and KM-Plotter, respectively. Mutation analysis was conducted using cBioPortal, immune cell infiltration via TIMER, and hub genes were identified through protein-protein interaction (PPI) networks. Biological functions and pathways were elucidated with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Finally, the expression of IL-17B, IL-17RB, and associated inflammatory cells in CRC were analyzed using immunohistochemical staining and special staining technique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Bioinformatics analysis showed that IL-17B gene and protein expression levels decreased, while IL-17RB expression increased in CRC. IL-17B expression was affected by gender, body weight, histology, lymph node status, and tumour grade. Overexpression of IL-17B was negatively correlated with progression-free survival in CRC. IL-17B is involved in phosphatidylinositol 3-kinase/AKT signaling, vascular development, and other processes. IL-17B is associated with mitochondrial gene expression, regulation of mRNA metabolism, amino acid metabolism and other processes, as well as phosphatidylinositol-binding and liganding. Inositol 3-kinase/AKT signalling and vascular development. IL-17B was negatively correlated with mitochondrial gene expression, regulation of mRNA metabolism, amino acid metabolism and other processes as well as with molecular functions such as phosphatidylinositol binding and ligase activity. IL-17RB expression was correlated with the clinicopathological features described above and decreased with tumour progression. High levels of IL-17RB were associated with improved overall survival and immune cell infiltration. The key genes of IL-17RB are mainly involved in DNA damage, metabolism, checkpoint signaling and regulation of replication. Immunohistochemical staining results showed that the expression of IL-17B and IL-17RB reduced in CRC, compared to normal colon tissue (&lt;em&gt;p&lt;/em&gt; &lt; 0.05). IL-17B was positively correlated with CD4&lt;sup&gt;+&lt;/sup&gt; T lymphocyte and mast cell infiltration. IL-17RB was positively correlated with CD4&lt;sup&gt;+&lt;/sup&gt; T lymphocyte infiltration and negatively correlated with CD20&lt;sup&gt;+&lt;/sup&gt; B lymphocyte infiltration.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;The expression of IL-17RB in CRC decreased with increasing tumour stage, and high levels of IL-17RB predicted a better prognosis, suggesting that its decreased expression was associated with disease progression. Therefore, IL-17RB may be a biomarker for assessing the prognosis of C","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155847"},"PeriodicalIF":2.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estrogen receptor subtypes and survival outcomes in non-small cell lung cancer","authors":"Rina Thaker ,&nbsp;Un Jung Lee ,&nbsp;Theodore J. Strange ,&nbsp;Cristina P. Sison ,&nbsp;Yue Faat Raymon Kwok ,&nbsp;Muhammad Rafay Khan Niazi ,&nbsp;Thomas Gut ,&nbsp;Nagashree Seetharamu ,&nbsp;Mario R. Castellanos","doi":"10.1016/j.prp.2025.155843","DOIUrl":"10.1016/j.prp.2025.155843","url":null,"abstract":"<div><h3>Aim</h3><div>Estrogen receptors (ERs), ERα and ERβ, are frequently detected in lung cancers, yet their prognostic impact on non-small cell lung cancer (NSCLC) outcomes remains uncertain. This study aims to assess the pooled prevalence and prognostic significance of ERα and ERβ in NSCLC, with a focus on gender differences.</div></div><div><h3>Methods</h3><div>We performed a systematic review and meta-analysis, identifying studies from major databases, including PubMed, Cochrane Library, and Embase, that reported ERα and ERβ expression and survival outcomes in NSCLC. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using random-effects models to assess associations with overall survival (OS). Heterogeneity was evaluated using the I² statistic, and publication bias was examined with funnel plots. Statistical analyses were conducted in R (version 4.3.0) utilizing the 'meta' package.\"</div></div><div><h3>Results</h3><div>Eighteen studies comprising 3842 patients met the inclusion criteria. ERα positivity was observed in 32 % of cases, whereas ERβ positivity was found in 60 %. ERα positivity in males was 53 %, and in females was 47 %. Meanwhile, ERβ positivity was seen in 49 % of males and 51 % of females. The pooled HR for ERα was 1.17 (95 % CI: 0.60–2.27), indicating no significant association with OS. However, ERβ positivity was linked to a statistically significant reduction in mortality risk (HR 0.85, 95 % CI: 0.72–0.99, p = 0.04). Subgroup analysis demonstrated a higher mortality hazard in males compared to females (HR 1.42, 95 % CI: 1.22–1.67, p &lt; 0.005).</div></div><div><h3>Conclusion</h3><div>NSCLC exhibits high rates of ERβ expression, which is linked to improved survival outcomes. In contrast, ERα expression is less prevalent, and its prognostic significance remains uncertain. These findings underscore ERβ as a promising therapeutic target in NSCLC, emphasizing the need for continued research into hormone-targeted treatments in lung cancer, especially given that approximately 50 % of both male and female patients with NSCLC express ERβ.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155843"},"PeriodicalIF":2.9,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “GDF6 in gastric cancer upregulated by helicobacter pylori induces epithelial-mesenchymal translation via the TGF-β/SMAD3 signaling pathway” [Pathol. - Res. Pract. 260 (2024) 155384]","authors":"Cuijuan Lu ,&nbsp;Xiangyu Fan ,&nbsp;Minying Zheng ,&nbsp;Shun Zhang ,&nbsp;Pan Wang ,&nbsp;Yanan Wang ,&nbsp;Shiwu Zhang","doi":"10.1016/j.prp.2025.155845","DOIUrl":"10.1016/j.prp.2025.155845","url":null,"abstract":"","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"267 ","pages":"Article 155845"},"PeriodicalIF":2.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary sarcomas of the bladder and prostate: A genomic landscape study","authors":"Dana Hariri ,&nbsp;Dean Pavlick ,&nbsp;Phillipe Spiess ,&nbsp;Roger Li ,&nbsp;Ashish Kamat ,&nbsp;Petros Grivas ,&nbsp;Neeraj Agarwal ,&nbsp;Shilpa Gupta ,&nbsp;Andrea Necchi ,&nbsp;Gennady Bratslavsky ,&nbsp;Alina Basnet ,&nbsp;Joseph Jacob ,&nbsp;Jeffrey Ross ,&nbsp;Oleksandr Kravtsov","doi":"10.1016/j.prp.2025.155840","DOIUrl":"10.1016/j.prp.2025.155840","url":null,"abstract":"<div><div>Primary sarcomas of the bladder and prostate are exceedingly rare, often highly aggressive and account for less than 1 % of all malignant tumors of these organs. In this landscape study, we searched for genomic biomarkers that could aid in either treatment selection or further classification of these tumors. 18 (0.2 %) bladder sarcomas were identified from 11,193 bladder cancers and 11 (0.6 %) prostate sarcomas were identified from 19,057 prostate cancers that underwent hybrid capture-based comprehensive genomic profiling (CGP) to assess all classes of genomic alterations (GA). The bladder sarcomas included 12 leiomyosarcomas, 3 rhabdomyosarcomas and 3 high-grade undifferentiated sarcomas. The sarcomas of the prostate featured 9 primary prostatic stromal sarcomas, 1 leiomyosarcoma and 1 rhabdomyosarcoma. The most frequent gene alterations were in <em>TP53</em>, <em>RB1</em> and <em>ATRX</em>. Bladder sarcomas were also found to have more than 2-fold more genetic alterations than compared to prostatic sarcomas.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"267 ","pages":"Article 155840"},"PeriodicalIF":2.9,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ATP ion channel-type P2X purinergic receptors as a key regulatory molecule in breast cancer progression","authors":"Xin-Hua Nie ,&nbsp;Teng-Zheng Li ,&nbsp;Cheng-Ming Peng","doi":"10.1016/j.prp.2025.155844","DOIUrl":"10.1016/j.prp.2025.155844","url":null,"abstract":"<div><div>Studies have confirmed that ATP ion channel P2X purinergic receptors play a key role in tumor growth and metastasis. Similarly, P2X purinergic receptors can be used as a favorable regulatory molecule of breast cancer cells to participate in the progression of breast cancer. There are abundant ATP and its cleavage products in breast cancer microenvironment, which can be used as natural activators of P2X purinergic receptors. P2X purinergic receptors play a role in regulating the growth and metastasis of breast cancer cells by mediating signal transduction, growth regulation and immune cell activity in microenvironment. However, the application of P2X purinergic receptors antagonist has the pharmacological characteristics of inhibiting the progression of breast cancer cells. Among P2X purinergic receptors, there is a close relationship between P2X7 receptor and breast cancer patients. P2X purinergic receptors can be used as a biological marker for breast cancer patients. In this paper, we discuss the functional role and regulatory molecular mechanism of P2X purinergic receptors in the progression of breast cancer. The pharmacological effects of P2X purinergic receptors selective antagonist on the growth, metastasis and invasion of breast cancer cells were further discussed. Therefore, P2X purinergic receptors can be used as a key regulatory molecule of breast cancer and a pharmacological target for potential therapy.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"267 ","pages":"Article 155844"},"PeriodicalIF":2.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143429850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental early mixed epithelial and stromal tumor of the efferent testicular-ductular system of the genitourinary tract: A small case series with literature review","authors":"Elaina Daniels ,&nbsp;Jesse McKenney ,&nbsp;Hikmat Al-Ahmadie ,&nbsp;Kyle Perry ,&nbsp;Rohit Mehra","doi":"10.1016/j.prp.2024.155797","DOIUrl":"10.1016/j.prp.2024.155797","url":null,"abstract":"<div><div>Mixed epithelial and stromal tumors (MEST) are rare, hormone-driven tumors of the genitourinary tract composed of stromal and epithelial components. They are rarely encountered in men, and it is exceedingly rare to find MESTs in efferent testicular-ductular structures. The current literature focuses on symptomatic men with macroscopically evident tumors. However, MESTs may present as incidental microscopic lesions and can easily be missed by the interpreting pathologist. Here, we discuss four cases of incidental low-grade MESTs of the seminal vesicle, ejaculatory duct, and epididymis. The patients were men ranged in age from 52 to 69 years old. Three were asymptomatic with elevated prostate specific antigen who were diagnosed with prostatic adenocarcinoma on core biopsies. Subsequent prostatectomies revealed MESTs with two cases involving the seminal vesicles and one involving the ejaculatory duct. The fourth patient presented with a testicular mass and was found to have vasitis nodosa, sperm granulomas, and a MEST of the epididymis. All four tumors demonstrated nodules composed of a bland spindled stroma and variable amounts of dilated glands lined by bland cuboidal epithelium. Immunohistochemistry showed stromal positivity for ER, PR, AR (patchy), and WT1 while the epithelial component expressed pancytokeratin, CK7, GATA3, AR, and PAX8 (weak), consistent with MEST. Low-grade incidental MESTs are usually benign with excellent long-term outcomes, although they can recur if incompletely excised or undergo malignant transformation. While these lesions are rarely reported, it is important to recognize the characteristic morphology and immunoprofile of MESTs to avoid misidentification and mismanagement of these tumors.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"268 ","pages":"Article 155797"},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143453834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sennoside B inhibits malignant phenotypes of triple-negative breast cancer cells and represses ERK/AKT/STAT5 signaling","authors":"Li-jun Li,&nbsp;Shan-shan Xie","doi":"10.1016/j.prp.2025.155842","DOIUrl":"10.1016/j.prp.2025.155842","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer. Treatment alternatives for TNBC are very limited and new therapeutic drugs are needed. Sennoside B (SB) is a dianthrone glycoside that has shown antitumor activity in osteosarcoma. However, the role of SB in TNBC remains unclear. This study aims to investigate the role and potential mechanism of SB in TNBC. MTT, colony formation, scratch, and Transwell assays were conducted to examine the malignant behaviors of TNBC cells under different doses of SB treatment. RT-qPCR and western blotting were utilized to detect mRNA or protein levels of molecules. The results revealed that SB treatment dose-dependently restrained TNBC cell proliferation, migration, invasiveness as well as epithelial-mesenchymal transition. Mechanistically, SB suppressed extracellular signal-regulated kinase (ERK), Ak strain transforming protein (AKT), and signal transducer and activator of transcription 5 (STAT5) phosphorylation in TNBC cells. In conclusion, SB treatment impairs the cell aggressiveness of TNBC and blocks ERK/AKT/STAT5 signaling in TNBC cells.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"269 ","pages":"Article 155842"},"PeriodicalIF":2.9,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}